At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Optimizing Prolonged Treatment In Myeloma Using MRD Assessment (OPTIMUM)
In Brief
A Phase 3 clinical trial evaluating Biospecimen Collection, Bone Marrow Aspirate, and 8 other interventions for Multiple Myeloma. Completed, enrolled 1 participant across 222 sites in 2 countries.
Detailed Summary
This phase III trial studies how well lenalidomide in combination with ixazomib works compared to lenalidomide alone in treating patients with evidence of residual multiple myeloma after stem cell transplantation. Lenalidomide may help shrink or slow the growth of multiple myeloma. Ixazomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving lenalidomide and ixazomib together may work better than giving lenalidomide alone in treating patients with evidence of residual multiple myeloma after a stem cell transplantation.
Study Details
Timeline
Interventions
Undergo collection of blood samples
Undergo bone marrow aspirate
Undergo bone marrow biopsy
Undergo CT scan
Given PO
Given PO
Given PO
Undergo PET scan
Ancillary studies
Ancillary studies